Combination therapy using durvalumab in patients with advanced soft tissue sarcoma: is doxorubicin best?

Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
Jin Li, Nianlan Zhou, Saiquan Lu +4
BMJ Open1 Oct 2026Peer-reviewedCC BY-NC 4.0Full textGeneral medicineCrossref
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial
Peter Schmid, Seock‐Ah Im, Zbigniew Nowecki +9
Nature Cancer8 Jun 2026Peer-reviewedCC BYFull text9 citedOncologyOpenAlex
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study
P. Schmid, H.-C. Wang, Filipa C. Lynce +19
Annals of Oncology20 May 2026Peer-reviewedCC BYFull text13 citedOncologyOpenAlex
FOLFOX plus nivolumab combination therapy for cisplatin-unfit patients with untreated advanced esophageal squamous cell carcinoma
Nozomu Ogura, Shun Yamamoto, Ryuichi Morita +9
Esophagus10 Jun 2026Peer-reviewedCC BY 4.0Full text2 citedSurgery & anaesthesiaPMC
Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in untreated locally advanced or metastatic EGFR-mutant NSCLC: a real-world, retrospective study in China
Xinwei Wu, Danni Wang, Yangbin Shi +8
BMC Medicine19 Oct 2026Peer-reviewedCC BY-NC-ND 4.0General medicineCrossref

Cite

BibTeX

@article{nakamura2026combination,
  title = {{Combination therapy using durvalumab in patients with advanced soft tissue sarcoma: is doxorubicin best?}},
  author = {Tomoki Nakamura and Masahiro Hasegawa},
  journal = {Translational cancer research},
  year = {2026},
  month = oct,
  doi = {10.21037/tcr-2026-2508},
  url = {https://europepmc.org/article/MED/42997724},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - Combination therapy using durvalumab in patients with advanced soft tissue sarcoma: is doxorubicin best?
AU  - Tomoki Nakamura
AU  - Masahiro Hasegawa
PY  - 2026
DA  - 2026/10/21
JO  - Translational cancer research
DO  - 10.21037/tcr-2026-2508
UR  - https://europepmc.org/article/MED/42997724
SN  - 2218-676X
SN  - 2219-6803
ER  -

Related

Cite